Genmab Takes Full Control of Acasunlimab Development Program
05 août 2024 05h50 HE
|
Genmab A/S
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
17 juil. 2024 06h25 HE
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
28 juin 2024 02h00 HE
|
Genmab A/S
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyFL is the second most common type of NHL and accounts for approximately 20-30 percent of all global...
Completion of Share Buy-back Program
27 juin 2024 17h00 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced...
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
26 juin 2024 19h03 HE
|
Genmab A/S
Company Announcement Approval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL...
Transactions in Connection with Share Buy-back Program
24 juin 2024 09h55 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
18 juin 2024 14h45 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The...
Transactions in Connection with Share Buy-back Program
17 juin 2024 09h33 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12 juin 2024 15h45 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
11 juin 2024 14h50 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...